Raghuram Selvaraju

Inovio Analyst Says Thermo Fisher Deal 'One Solid Step' Toward COVID-19 Vaccine Commercialization
Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally
Evoke Gets FDA Nod For Gimoti, A Nasally-Administered Gastroparesis Drug
Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally
Evoke Gets FDA Nod For Gimoti, A Nasally-Administered Gastroparesis Drug
Sorrento Rallies On EUA Filing For Rapid COVID-19 Antibody Test Kit
Inovio Analysts Bullish On Prospects For Coronavirus Vaccine, Biotech's Pipeline

Raghuram Selvaraju Recent News

Inovio Analysts Project About 24% Upside Potential Amid Optimism On Coronavirus DNA Vaccine
Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO) announced the completion of enrollment in the Phase 1 trial of its COVID-19 DNA vaccine INO-4800 and
Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption
Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More
Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation
HC Wainwright Says Aerpio Pharma Flies Under The Radar Due To OTC Listing, Projects 150% Upside
HC Wainwright Takes Bullish Stance On Two Cancer-Focused Pharma Companies
HTG Molecular's Deal With Merck KGaA 'Provides Further Validation' For EdgeSeq Technology
What You Should Know About The Drug Approval Valeant Could Receive This Week
What's The FDA Saying About Valeant's Manufacturing Facility Issues?
An 'Unsung Potential Winner,' ObsEva Initiated At Buy
FDA Removes Clinical Hold On Inovio Pharma's VGX-3100, Its First Drug To Enter A Pivotal Study
Inovio's HIV Vaccine Elicits High Response Rates In Phase 1 Trial
Alimera's Commercial Steroid Implant For Diabetic Macular Edema, Explored
What Synergy's New Patents Mean For Its Commercial Prospects
Analyst: Synergy Pharma Could Achieve Sustainable Profitability By 2018
More Than 100% Upside Seen In Imprimis After Q4 Results
Synergy's Safety Profile Should Boost Trulance Uptake, Takeover Prospects Remain Favorable
Synergy Pharma's Plecanitide Finally Crosses The Finish Line; Rodman & Renshaw Lifts Price Target To $18
Synergy Hits Endpoints, Earns A Price Target Bump At Rodman & Renshaw
With Valeant's Continued Deterioration, Rodman & Renshaw Downgrades To Neutral
Rodman & Renshaw Prescribe A $6 Price Target For Cancer Genetics
Sum-Of-The-Parts Valuation Leads Rodman & Renshaw To Initiate Oasmia Pharmaceuticals At Buy With A $6 Target
Inovio Initiates Second Zika Vaccine Human Trial; Wainwright Reiterates Buy Rating